The ANKRD12 Knouckout A-549 Polyclonal Cells product comprises a CRISPR/Cas9-engineered heterogeneous A-549 cell population with targeted disruption of the ANKRD12 locus, providing a loss-of-function model that retains polyclonal diversity. This format avoids single-cell cloning artifacts and enables robust functional genomics studies in a lung adenocarcinoma background.
The parental A-549 cell line is an epithelial model derived from lung adenocarcinoma tissue of a 58-year-old Caucasian male, widely employed in oncology research for its reproducible growth and drug response profiles. Its relevance to non-small cell lung cancer makes it a standard host for gene knockout experiments aimed at dissecting oncogenic mechanisms.
ANKRD12 functions as a scaffold protein that bridges activated Wnt/??-catenin signaling to transcriptional repression by recruiting histone deacetylases HDAC1 and HDAC2. Upon Wnt stimulation, ??-catenin accumulates and partners with TCF/LEF transcription factors; ANKRD12 interacts with this complex and tethers HDACs to chromatin, silencing target genes involved in proliferation and differentiation. Canonical pathway components??Wnt ligands, Frizzled, LRP5/6, Dishevelled, GSK-3??, AXIN, and APC??converge on ??-catenin regulation, and ANKRD12 knockout relieves this repression, leading to derepression of cell cycle regulators and other downstream effectors.
In A-549 lung adenocarcinoma cells, loss of ANKRD12 is predicted to enhance Wnt-driven proliferative and tumorigenic phenotypes by removing a key brake on target gene expression. This polyclonal knockout model facilitates investigation of ANKRD12??s tumor-suppressive functions and its crosstalk with upstream Wnt ligands and ??-catenin. Although human genetics links ANKRD12 to intellectual disability and developmental delay, its emerging role in colorectal and lung adenocarcinomas underscores the product??s utility for exploring tissue-specific oncogenic processes and therapeutic vulnerabilities.
Research applications include transcriptional profiling by RT-qPCR or RNA-seq to capture gene expression changes, Western blotting for ANKRD12, HDAC1/2, and ??-catenin protein levels, and functional assays such as proliferation, colony formation, migration, invasion, and apoptosis. Chromatin immunoprecipitation (ChIP-qPCR) can monitor HDAC occupancy at Wnt target loci, while Wnt reporter assays directly quantify pathway activity. These approaches support lung cancer biology, drug target validation, and signaling pathway dissection. For further information or to discuss custom configurations, please contact Ascent Research.
